(Q46630423)
Statements
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers (English)
Ghassan K Abou-Alfa
Eric K Rowinsky
Gary K Schwartz
David P Kelsen
Sunil Sharma
Eve Siegel
Carlos R Becerra
S Gail Eckhardt
Kevie Feit